SEC Comment Letter for Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF) — May 6, 2020
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: May 6, 2020 · CIK: 0001601936 · Accession: 0000000000-20-003954
AI Filing Summary & Sentiment
File numbers found in text: 333-237907
Letter
United States securities and exchange commission logo May 6, 2020 Thomas Meyer Chief Executive Officer Auris Medical Holding Ltd. Clarendon House 2 Church Street Hamilton HM 11 Bermuda Re:Auris Medical Holding Ltd. Registration Statement on Form F-1 Filed April 29, 2020 File No. 333-237907 Dear Mr. Meyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell, Attorney-Adviser, at (202) 551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 6, 2020
Thomas Meyer
Chief Executive Officer
Auris Medical Holding Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
Re:Auris Medical Holding Ltd.
Registration Statement on Form F-1
Filed April 29, 2020
File No. 333-237907
Dear Mr. Meyer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell, Attorney-Adviser, at (202) 551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences